| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net cash used in operating activities | -10,113,975 | -7,378,099 |
| Proceeds from issuance of common stock, net | 9,863,883 | - |
| Proceeds from exercise of warrants and stock options | 605 | 605 |
| Net cash provided by financing activities | 9,864,488 | 605 |
| Net decrease in cash, cash equivalents, and restricted cash | -249,487 | -7,377,494 |
| Cash and cash equivalents at beginning of period | 19,192,440 | - |
| Cash and cash equivalents at end of period | 18,942,953 | - |
Marker Therapeutics, Inc. (MRKR)
Marker Therapeutics, Inc. (MRKR)